Autopsy report · NCT04713202

Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl

“Funder decision”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Chandrikha Chandrasekhara

Sponsor type

University, hospital or other

Conditions

Neuroendocrine Tumors; Carcinoid Syndrome; Diarrhea

Interventions

Telotristat ethyl; Peptide Receptor Radionuclide Therapy; Placebo

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma
  “due to a development decision by the funder” (70% match in meaning)
• Evaluating the CAREchart@Home™ Program for Enhancing After-hours Cancer Care
  “Due to unforeseen circumstances, the funder decided to discontinue all funding.” (58% match in meaning)
• MISP 60528 Pneumococcal Vaccination
  “Termination of funding by the sponsor/funder.” (57% match in meaning)
• Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)
  “Business decision.” (55% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.